Drug
Dasatinib clinical trials
Also written Sprycel and BMS-354825.
- studies test it
- 282
- open now
- 27
- in phase 3
- 18
- first study started
- 2001
Keep track of what changes. Save the Dasatinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
280 studies that test it; most in 2007 (37); 1 more planned to start later
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2003 | 2 |
| 2004 | 4 |
| 2005 | 11 |
| 2006 | 14 |
| 2007 | 37 |
| 2008 | 24 |
| 2009 | 34 |
| 2010 | 7 |
| 2011 | 14 |
| 2012 | 15 |
| 2013 | 9 |
| 2014 | 9 |
| 2015 | 12 |
| 2016 | 18 |
| 2017 | 8 |
| 2018 | 6 |
| 2019 | 3 |
| 2020 | 9 |
| 2021 | 6 |
| 2022 | 10 |
| 2023 | 8 |
| 2024 | 7 |
| 2025 | 9 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 4
- Phase 1
- 95
- Phase 2
- 185
- Phase 3
- 18
- Phase 4
- 8
- No phase
- 8
What it is tested for
Each study’s main condition, where its own words name it.
- Leukemia
- 16
Who runs them
Industry 54 · Other 228
Bristol-Myers Squibb (46) · National Cancer Institute (NCI) (32) · M.D. Anderson Cancer Center (23) · St. Jude Children's Research Hospital (7) · Mayo Clinic (6) · Duke University (6) · Memorial Sloan Kettering Cancer Center (4) · OHSU Knight Cancer Institute (4)
Often tested with
Tested in the same studies.
Imatinib (21) · Quercetin (19) · Nilotinib (10) · Erlotinib (10) · Cytarabine (9) · Dexamethasone (8) · Prednisone (8) · Venetoclax (7)
Studies
Open first, then newest update. How each study uses Dasatinib is read from its arms, and is right about nine times in ten.
Testing it · 282
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2National Cancer Institute (NCI)NCT06124157Written as Dasatinib
- Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseRecruitingPhase 2M.D. Anderson Cancer CenterNCT07269470Written as Dasatinib
- Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual DiseaseRecruitingEarly Phase 1Mayo ClinicNCT07025226Written as Dasatinib
- Asciminib Frontline Risk AdaptedNot yet recruitingPhase 2Prof. Dr. med. Andreas HochhausNCT07804901Written as Dasatinib 80mg QD (5 days per week)
- Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple MyelomaRecruitingPhase 2Mayo ClinicNCT06940297Written as Dasatinib
- Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationRecruitingPhase 2Medical College of WisconsinNCT04838041Written as Dasatinib
- Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)RecruitingPhase 2St. Jude Children's Research HospitalNCT06390319Written as Dasatinib
- Dasatinib for HIV-1 Reservoir ReductionRecruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT07342491Written as Dasatinib
- Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in KoreaRecruitingPhase 2Hyoung Jin KangNCT06257394Written as Dasatinib(Sprycel) arm
- Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and LymphomaRecruitingPhase 2St. Jude Children's Research HospitalNCT06533748Written as Dasatinib
- Asciminib Roll-over StudyRecruitingPhase 4Novartis PharmaceuticalsNCT04877522Written as Dasatinib
- Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)RecruitingPhase 2University of ChicagoNCT04747912Written as Dasatinib
- Senescence in Chronic Kidney DiseaseEnrolling by invitationPhase 2Mayo ClinicNCT02848131Written as Group 2: Dasatinib
- COAST Therapy in Advanced Solid Tumors and Prostate CancerRecruitingPhase 1/2Medical University of South CarolinaNCT05036226Written as Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingPhase 2Canadian Cancer Trials GroupNCT03297606Written as Dasatinib
- Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older SubjectsRecruitingPhase 2/3Cedars-Sinai Medical CenterNCT05653258Written as Dasatinib 100 MG
- Senolytics for Secondary Progressive MSNot yet recruitingPhase 1Ohio State UniversityNCT07270120Written as Dasatinib and quercetin
- ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CMLRecruitingPhase 1Marlise Luskin, MDNCT03595917Written as Dasatinib
- HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesRecruitingPhase 1/2Princess Maxima Center for Pediatric OncologyNCT05751044Written as Dasatinib
- Newly-diagnosed Pediatric T-cell ALL ProtocolRecruitingPhase 2/3Institute of Hematology & Blood Diseases Hospital, ChinaNCT06855810Written as Dasatinib
See all 282 studies that test Dasatinib →
Given in every arm · 25 — Dasatinib is usual care beside what is tested
- Pediatric Precision Laboratory Advanced Neuroblastoma TherapyRecruitingPhase 2Giselle ShollerNCT02559778Written as dasatinib
- Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CMLNot yet recruitingPhase 2The University of Hong KongNCT07493408Written as Dasatinib
- KRT-232 and TKI Study in Chronic Myeloid LeukemiaRecruitingPhase 1/2Kartos Therapeutics, Inc.NCT04835584Written as Dasatinib
- Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and NavitoclaxActive, not recruitingPhase 1/2St. Jude Children's Research HospitalNCT05192889Written as Dasatinib
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in AdultsActive, not recruitingPhase 3National Cancer Institute (NCI)NCT04530565Written as Dasatinib
- Frontline Asciminib Combination in Chronic Phase CMLActive, not recruitingPhase 2University of JenaNCT03906292Written as Dasatinib
- Psma Intensity Can be Altered by Androgen and Phospho-SrC ObstructionCompletedPhase 2St Vincent's Hospital, SydneyNCT04925648Written as Dasatinib
- Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04329325Written as dasatinib
- A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic MalignanciesActive, not recruitingPhase 1Kumquat Biosciences Inc.NCT06645886Written as Dasatinib
- Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid LeukemiaActive, not recruitingPhase 2SWOG Cancer Research NetworkNCT03654768Written as Dasatinib
- Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase InhibitorsTerminatedPhase 1M.D. Anderson Cancer CenterNCT01751425Written as Dasatinib
- A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.CompletedPhase 1Hoffmann-La RocheNCT04580121Written as Dasatinib
- A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALLCompletedPhase 1Novartis PharmaceuticalsNCT02081378Written as Dasatinib
- Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaCompletedPhase 2University of WashingtonNCT03023046Written as Dasatinib
- Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic LymphomaTerminatedPhase 2University of California, San DiegoNCT02043587Written as Dasatinib
- Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic LeukemiaTerminatedPhase 1St. Jude Children's Research HospitalNCT03515200Written as Dasatinib
- Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDSWithdrawnPhase 1/2Bio-Path Holdings, Inc.NCT02923986Written as Dasatinib
- Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic LeukemiaCompletedPhase 1OHSU Knight Cancer InstituteNCT02779283Written as Dasatinib
- A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid LeukemiaCompletedPhase 1Bristol-Myers SquibbNCT02011945Written as Dasatinib
- A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCCTerminatedPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT00882583Written as Dasatinib
Showing 20 of 25.
As the comparator · 4 — what is tested is compared with Dasatinib
- A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPNot yet recruitingPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07885293Written as Dasatinib
- A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPActive, not recruitingPhase 3Novartis PharmaceuticalsNCT04971226Written as Dasatinib
- Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and AdolescentsActive, not recruitingPhase 3Dana-Farber Cancer InstituteNCT03020030Written as DASATINIB
- Comparative Bioavailability of XS004 (Dasatinib) Formulation G and SPRYCEL® (Dasatinib) in Healthy, Adult Subjects Under Fasting ConditionsCompletedPhase 1Xspray Pharma ABNCT05439408Written as Dasatinib 140 MG [Sprycel]
Codes
What other systems call Dasatinib · ClinicalTrials.gg INT006575
- MeSH (NLM) D000069439DasatinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) RBZ1571X5HDASATINIBConfirmed FDA, NLM, Wikidata
- RxNorm 475342Confirmed FDA, Wikidata
- Wikidata Q27139135dasatinib monohydrateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C38713DasatinibConfirmed FDA, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069439 | Dasatinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | RBZ1571X5H | DASATINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 475342 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27139135 | dasatinib monohydrate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C38713 | Dasatinib | Confirmed FDA, Wikidata |
Also registered as dasatinib anhydrous (UNII X78UG0A0RN · RxNorm 1546019).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.